Drug Search Results
More Filters [+]

Selodenoson

Alternative Names: selodenoson, dti-0009, dti0009, dti 0009
Latest Update: 2005-06-24
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ADORA1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aderis
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Selodenoson

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Atrial Fibrillation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DTI-0009/003

P2

Completed

Atrial Fibrillation

None

Recent News Events

Date

Type

Title